Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Erica D. Greanya"'
Autor:
Nawal Al Nahdi, Jo-Ann Ford, Erica D. Greanya, Jo-Ann Harrigan, Irene Tse, Urs P. Steinbrecher, Siegfried R. Erb, Eric M. Yoshida
Publikováno v:
Annals of Hepatology, Vol 12, Iss 1, Pp 156-160 (2013)
Fibrosing cholestatic hepatitis (FCH) is a less common but well-recognized severe complication of recurrent hepatitis C virus (HCV) infection post-liver transplant. This condition is fatal without successful treatment and to date; post-transplant ant
Externí odkaz:
https://doaj.org/article/088149d622904119bc462fe8bd5f866e
Publikováno v:
Annals of Hepatology, Vol 11, Iss 2, Pp 179-185 (2012)
Purpose. Chronic hepatitis C virus (HCV) is a major problem affecting up to 170 million people worldwide. Two protease inhibitors have recently been approved that will revolutionize treatment. Our objective was to summarize and evaluate the literatur
Externí odkaz:
https://doaj.org/article/59ae163287cc4f1e8a19d164a019b7cb
Publikováno v:
Annals of Hepatology, Vol 10, Iss 4, Pp 441-444 (2011)
Introduction. Hepatitis B virus (HBV) related liver transplant (LT) recipients face a high risk of HBV reinfection in the absence of continuous post-operative HBV prophylaxis. Combination HBV prophylaxis with hepa-titis B immune globulin (HBIg) and n
Externí odkaz:
https://doaj.org/article/52c8a416ed3a412691e13e69bd23a95b
Autor:
Janakie Singham, Erica D. Greanya, Kirby Lau, Siegfried R. Erb, Nilu Partovi, Eric M. Yoshida
Publikováno v:
Annals of Hepatology, Vol 9, Iss 2, Pp 166-171 (2010)
Background. Patients who receive liver transplantation for chronic hepatitis B infection require long-term combination therapy with hepatitis B immunoglobulin (HBIG) and oral antiviral medication to prophylax against graft re-infection. This study ex
Externí odkaz:
https://doaj.org/article/e90751165896426daae50cb6664eff60
Autor:
Maznar Haque, Almoutaz Hashim, Erica D. Greanya, Urs P. Steinbrecher, Siegfried R. Erb, Eric M. Yoshida
Publikováno v:
Annals of Hepatology, Vol 9, Iss 2, Pp 202-206 (2010)
Recurrent hepatitis C virus (HCV) infection after liver transplantation is a significant cause of morbidity, mortality and graft loss. Spontaneous clearance of recurrent HCV after liver transplant is a rarely reported phenomenon. We report a case of
Externí odkaz:
https://doaj.org/article/6e59e73cf3c54c96b6daef2f9e9b7be5
Autor:
Ian S.H. Cadden;, Erica D. Greanya;, Siegfried R. Erb;, Charles H. Scudamore;, Eric M. Yoshida
Publikováno v:
Annals of Hepatology, Vol 8, Iss 2, Pp 158-161 (2009)
Portopulmonary hypertension (PPH) is an infrequent, but well-recognized complication of liver cirrhosis. PPH in those with end-stage liver disease has a significant impact on per-operative and intra-operative mortality, with liver transplantation bei
Externí odkaz:
https://doaj.org/article/31605b25ffdc4cc89ca55309d1d7ba60
Publikováno v:
Canadian Journal of Gastroenterology, Vol 26, Iss 4, Pp 205-210 (2012)
OBJECTIVE: To summarize and evaluate the published literature pertaining to boceprevir and telaprevir, and to provide clinicians with suggestions for use in patients with chronic hepatitis C infection.
Externí odkaz:
https://doaj.org/article/2368136db89d419ea5d94a767f58731b
Publikováno v:
International Journal of Clinical Pharmacy. 39:468-472
Background With an increasing number of options for atrial fibrillation (AF) stroke prophylaxis, there are several medication-related factors to consider. This study aimed to gain a better understanding of which preference factors influence patient d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62e38f97707f3275c8bc83cb5c5b13e0
https://doi.org/10.1007/s11096-017-0440-8
https://doi.org/10.1007/s11096-017-0440-8
Autor:
Jo-Ann Harrigan, Jo-Ann Ford, Urs P. Steinbrecher, Eric M. Yoshida, Siegfried R. Erb, Nawal Al Nahdi, Irene Tse, Erica D. Greanya
Publikováno v:
Annals of Hepatology, Vol 12, Iss 1, Pp 156-160 (2013)
Fibrosing cholestatic hepatitis (FCH) is a less common but well-recognized severe complication of recurrent hepatitis C virus (HCV) infection post-liver transplant. This condition is fatal without successful treatment and to date; post-transplant ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::132a5b3f607a28be71ddbff674c32267
https://doi.org/10.1016/s1665-2681(19)31400-0
https://doi.org/10.1016/s1665-2681(19)31400-0
Autor:
Nilufar Partovi, Eric M. Yoshida, Erica D. Greanya, R.J. Shapiro, Robert D. Levy, E.H.Z. Wang
Publikováno v:
Transplant Infectious Disease. 14:519-525
Background Solid organ transplant (SOT) recipients are at risk for Pneumocystis pneumonia (PCP), especially in the first year post transplant. Although trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis substantially decreases this risk, there is li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97535df01f7392f621ccaf41eed772ad
https://doi.org/10.1111/j.1399-3062.2012.00740.x
https://doi.org/10.1111/j.1399-3062.2012.00740.x